Endocrine Abstracts

Background: Pancreatic Enzyme Insufficiency (PEI) is a recognised potential consequence of pancreatic pathology and / or somatostatin analog therapy. It is known to be detrimental to patient quality of life and nutritional status (1). Patients with PEI can experience gastrointestinal symptoms, vitamin and micronutrient deficiencies, malnutrition, and even reduced survival (2). Pancreatic enzyme replacement therapy (PERT) is the expert guideline recommended treatment for PEI, a...

Background: Pancreatic Enzyme Replacement Therapy (PERT) is the gold standard treatment for Pancreatic Enzyme Insufficiency (PEI), regardless of underlying aetiology. Historically, there have been intermittent PERT supply issues, however, over the past year (2023/4) this has become a more persistent and significant issue: leading to questions being raised in both UK and EU parliaments and main media reports. PERT is potentially life-saving: for those with certain conditions, i...

Neuroendocrine cancers represent the tenth most prevalent type of cancer in England. However, people with neuroendocrine cancer currently face significant inequities throughout the entire care pathway – from suspected cancer to follow-up care. Despite expert clinical guidelines, there is no currently available national Neuroendocrine Cancer Patient Referral and Care Pathway. Guiding principles of optimal patient pathways include the promotion of earlier, accurate diagnosi...